Strategic Intelligence Report
Generated July 29, 2026
Semiconductor Manufacturing
Axcelis Technologies
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
1
Chokepoint Score
1 other entity structurally depend on this one
Steady
Momentum
insider filing activity unchanged since last check
Headquarters
Beverly, Massachusetts, USA
Website
Employees
1,465 (as of Dec 31, 2025, 10-K)
Founded
1978
Listing
ACLS · NASDAQ
Market Cap
$3.94B
Revenue (TTM)
$845.44M
Price
USD128.11 (-2.73%)
Market data as of Jul 28, 2026, 11:21 AM · Source: Yahoo Finance (delayed). Not investment advice.
Overview
A US-based maker of ion implantation equipment, a specialized process step in semiconductor manufacturing used to precisely modify the electrical properties of silicon wafers. Axcelis Technologies reported full-year 2025 revenue of $839.0 million (98.2% from its ion implantation business) with operating profit of $119.3 million (down from $210.8 million in 2024); power-device-focused ion implantation represented 55% of the value of 2025 system shipments, with Wall Street projecting growth resuming to an estimated $921 million in 2027.
Dependency Map
One hop in each direction — see Strategic Connections below for the full, sourced breakdown of every relationship.
Strategic Connections
Supply Chain
- Taiwan Semiconductor Manufacturing Company: Axcelis supplies ion implantation equipment used in advanced chip manufacturing processes.
Competition / Other
- Applied Materials: Axcelis competes with Applied Materials' ion implantation product line, though Axcelis specializes as a pure-play implant equipment maker.
Strategic Risks
- Smaller, niche equipment category with concentrated demand
Future Outlook
- Steady demand tied to overall wafer fab equipment cycles
Sources
- U.S. Securities and Exchange Commission (EDGAR) (Feb 2026) — Axcelis Technologies, Inc. FY2025 Annual Report (Form 10-K), filed with the SEC
- SEC 10-K filing / Motley Fool analysis (May 2026) — Axcelis reports $839M in 2025 revenue, with ion implantation representing 98% of sales
- SEC 10-K filing (FY2025) (Feb 2026) — Axcelis' power-device implant systems accounted for 55% of 2025 system shipment value
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Full Analyst Report — switch to the Executive Summary.